Catherine Sabatos-Peyton, Larkspur CEO

Lark­spur Bio­sciences kicks off with $30M+, hunt­ing for new on­col­o­gy im­munother­a­pies

Based in Mass­a­chu­setts, Lark­spur Bio­sciences, a biotech fo­cused on de­vel­op­ing new im­muno-on­col­o­gy treat­ments, is now armed with $35.5 mil­lion in com­bined …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.